TVRD

#4507
Tvardi Therapeutics, Inc. - Common Stock
1.7 5 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.75
1.75
Jahresspanne
1.50
5.69
Tagesänderung
-2.78%
Monatliche Änderung
-16.27%
6 month change
-54.90%
Jahresänderung
-51.39%
Vorheriger Schlusskurs
1.8 0
Open
1.7 5
Tief
1.7 5
Hoch
1.7 5
Volumen
5
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Tvardi Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Tvardi Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tvardi Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Tvardi Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Tvardi Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Tvardi Therapeutics, Inc. current report, Q1 FY2026
8-K

Tvardi Therapeutics, Inc. current report, 03 June 2021

Full document

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by Cara Therapeutics, Inc. on June 3, 2021. The filing details the voting results for three proposals submitted to security holders. Note: The request metadata references "Tvardi Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Cara Therapeutics, Inc."

Key Financial Metrics

This filing is a Current Report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

The filing reports the outcomes of three stockholder proposals:

  • Proposal 1 (Election of Directors): Harrison M. Bains, Jr. and Dr. Susan Shiff, Ph.D. were elected to the Board of Directors until the 2024 Annual Meeting.
    • Harrison M. Bains, Jr.: 28,448,858 votes For; 836,904 votes Withheld.
    • Susan Shiff, Ph.D.: 27,902,976 votes For; 1,382,786 votes Withheld.
  • Proposal 2 (Executive Compensation): Stockholders approved the compensation of Named Executive Officers on a non-binding advisory basis.
    • 28,190,965 votes For; 979,010 votes Against; 115,787 Abstentions.
  • Proposal 3 (Auditor Ratification): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2021.
    • 39,581,075 votes For; 1,661,532 votes Against; 39,035 Abstentions.

Guidance, Outlook, and Risks

This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the submission of matters to a vote of security holders.

Investor Verification Checklist

  • Verify the correct registrant name is Cara Therapeutics, Inc. (Ticker: CARA), not Tvardi Therapeutics.
  • Confirm the tenure of the newly elected directors (Harrison M. Bains, Jr. and Susan Shiff, Ph.D.) extends to the 2024 Annual Meeting.
  • Note that the auditor ratification applies specifically to the fiscal year ending December 31, 2021.
  • Review the Proxy Statement filed on April 23, 2021, for detailed descriptions of the proposals and executive compensation specifics.